Canaccord Genuity analyst William Plovanic maintained a Buy rating on TriSalus Life Sciences (TLSI – Research Report) yesterday and set a price target of $11.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
William Plovanic has given his Buy rating due to a combination of factors that highlight TriSalus Life Sciences’ promising growth trajectory. The company has reported a robust operational quarter, with a significant year-over-year revenue increase, aligning with expectations and slightly surpassing consensus estimates. This growth is largely driven by the anticipated acceleration in sales of TriNav, particularly in the latter half of 2025. The management’s reaffirmation of a 50% revenue growth guidance for 2025, despite shifting profitability expectations to 2026, underscores a strong commitment to expanding their commercial operations and clinical applications.
Furthermore, the introduction of a new reimbursement code for pre-procedure mapping is expected to enhance the utilization of TriNav, providing economic incentives for physicians and potentially leading to sustainable adoption. The company’s strategic focus on its medical device business, with investments in new product launches and clinical studies, positions it well for future growth. Although there are challenges in the financing landscape for early-stage biotech assets, TriSalus’s solid device business and product pipeline, supported by recent financing, offer a compelling case for long-term growth, justifying the Buy rating and the $11 price target.
In another report released on April 30, Northland Securities also reiterated a Buy rating on the stock with a $12.50 price target.